VERAXA Biotech (NASDAQ: VRXA) is expanding its use of human-relevant testing methods across its oncology research programs, a move that could reshape how the Switzerland-based company generates preclinical data for its antibody-based cancer therapies. The strategy, announced on October 7, 2026, centers on New Approach Methodologies (NAMs), a collection of non-animal research techniques that includes cell-based assays and computational modeling. By implementing these methods, VERAXA aims to produce more clinically informative data while reducing the number of animals required for drug development.
The importance of this shift lies in its potential to improve the translation of preclinical findings to human biology. Traditional animal models often fail to predict human responses, leading to costly late-stage failures in oncology drug development. VERAXA’s adoption of NAMs, which are aligned with U.S. Food and Drug Administration guidance, supports the development of its BiTAC(R) T-cell engagers, BiTAC-based antibody-drug conjugates, and bispecific antibody-drug conjugates for cancer treatment. According to the company, new three-dimensional spheroid data reinforce the ability of its models to assess the dual-target specificity of its lead T-cell engager candidates.
A key implication is the substantial reduction in animal use. An ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer required about 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies. The company reports that its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity. This suggests that human-relevant testing can deliver robust efficacy signals with far fewer animals, addressing both ethical and efficiency concerns.
For investors, the announcement signals a commitment to more predictive preclinical development, which could increase the probability of success for VERAXA’s pipeline. The company, which has a key financial and regulatory presence in the U.S., is positioning itself as an emerging leader in designing novel cancer therapies. The full details of the announcement are available through the original release, and further information about VERAXA Biotech can be found on its client partner page. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
